Hit Discovery at Pivot Park Screening Centre within the European Lead Factory
Watch this webinar to learn about:
- Pivot Park Screening Centre (PPSC) contributions to the European Lead Factory (ELF);
- Hit finding efforts for > 70 crowd-sourced drug targets;
- Lessons learnt from assay development and uHTS output within ELF.
PPSC is a partner in the European Lead Factory (ELF), a collaborative public-private partnership funded by the Innovative Medicines Initiative. ELF provides researchers in Europe with a unique early drug discovery platform to translate innovative biology and chemistry concepts into high-quality starting points for drug discovery. In collaboration with its partners at European Screening Centre (ESC), PPSC continues to carry out assay development and all of uHTS activities in public target programs. This webinar will provide you with insights on the overall hit finding efforts at PPSC for > 70 crowd sourced drug targets between 2013 and 2018.
About the presenter:
Dr. Saman Honarnejad – Director Drug Discovery at Pivot Park Screening Centre is a biotechnologist with over a decade of experience in high-throughput biology. At Pivot Park Screening Centre (PPSC) in Oss, the Netherlands, he is involved in cellular and biochemical assay development, ultra high-throughput screening (uHTS) and hit-to-lead biological compound profiling within a wide range of commercial, academic and public-private partnership projects including the European Lead Factory (ELF).
Prior to joining PPSC in 2017, he was active in high-content compound profiling method development at Max-Planck Institute (Germany), Harvard Medical School (United States) and Heidelberg University (Germany) and further optimized microarray-based cDNA/RNAi functional screening assays at the European Molecular Biology Laboratory (EMBL).